Teacher Retirement System of Texas Grows Stock Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Teacher Retirement System of Texas grew its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 56.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,250,000 shares of the company’s stock after purchasing an additional 450,000 shares during the period. Teacher Retirement System of Texas’ holdings in Stevanato Group were worth $27,238,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Hardy Reed LLC lifted its holdings in shares of Stevanato Group by 8.2% during the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after purchasing an additional 840 shares during the last quarter. First Bank & Trust raised its holdings in Stevanato Group by 7.3% in the 4th quarter. First Bank & Trust now owns 15,145 shares of the company’s stock worth $330,000 after acquiring an additional 1,036 shares during the last quarter. Truist Financial Corp raised its holdings in Stevanato Group by 4.2% in the 4th quarter. Truist Financial Corp now owns 26,900 shares of the company’s stock worth $586,000 after acquiring an additional 1,073 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Stevanato Group by 9.7% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,874 shares of the company’s stock worth $281,000 after acquiring an additional 1,141 shares during the last quarter. Finally, US Bancorp DE raised its holdings in Stevanato Group by 17.9% in the 4th quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after acquiring an additional 1,295 shares during the last quarter.

Stevanato Group Price Performance

Shares of STVN opened at €22.52 ($24.48) on Friday. The firm has a market cap of $6.82 billion, a PE ratio of 47.91, a P/E/G ratio of 7.18 and a beta of 0.60. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm has a fifty day simple moving average of €21.03 and a two-hundred day simple moving average of €20.60. Stevanato Group S.p.A. has a 1-year low of €16.56 ($18.00) and a 1-year high of €33.49 ($36.40).

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. On average, equities analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Analysts Set New Price Targets

STVN has been the subject of a number of recent analyst reports. UBS Group decreased their price objective on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a report on Friday, March 7th. Morgan Stanley restated an “equal weight” rating and issued a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Bank of America boosted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. William Blair restated an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th. Finally, Wolfe Research assumed coverage on shares of Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stevanato Group presently has a consensus rating of “Moderate Buy” and an average target price of €27.75 ($30.16).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.